NCT02672436已完成2 期
A Randomized, Double-Blind, Vehicle-controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of ENERGI-F703 in Subjects With Diabetic Foot Ulcers
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 141
- 试验地点
- 1
- 主要终点
- The ulcer closure rate
研究概览
简要总结
The objective of this study is to evaluate the efficacy and safety of ENERGI-F703 in subject with diabetic foot ulcers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •With either gender aged at least 20 years old
- •With diagnosed diabetic mellitus (DM), e.g. currently under DM medication treatment or naïve DM subject with duplicated HbA1c over 6.5% and fasting plasma glucose over 126 mg/dL measured at least one week apart before Screening)
- •With at least one cutaneous ulcer on the foot (including ulcers on the lower legs) and not healing for at least 4 weeks. The largest diabetic foot ulcer will be selected as target ulcer. If two or more ulcers have the largest size, the one with worst grade will be selected. If two or more ulcers have the largest size and grade, the one with longest duration will be selected.
- •The target ulcer is classified as grade 1 to 3 ulcer according to Wagner Grading System and with ulcer size of 1 cm2 to 36 cm2 (Grade 3 ulcer subject may enter the study only if after debridement, the abscess of target ulcer is under control at investigator's discretion and osteomyelitis does not present)
- •Diabetic foot ulcers should be free of any necrosis or infection in any soft tissue and bone tissue;
- •Subject has signed the written informed consent form
排除标准
- •With active osteomyelitis
- •With target ulcer size decreased by at least 30% after at least 2 weeks of standard-of-care-only period or any other recorded regular therapy either before Screening visit or after completing Initial Phase
- •With poor nutritional status (albumin < 2g/dl), poor diabetic control (HbA1c > 12%), a leukocyte counts < 2,000/mm3, abnormal liver function (AST, ALT>3 x upper limit of normal range) within 14 days before Screening visit or 28 days before Randomization visit Note: HbA1c: hemoglobin A1c; AST: aspartate aminotransferase; ALT: alanine aminotransferase
- •Requiring treatment with systemic corticosteroids, immunosuppressive or chemotherapeutic agents
- •With known or suspected hypersensitivity to any ingredients of study product and vehicle
- •With coronary heart disease with myocardial infarction, coronary artery bypass graft (CABG), or percutaneous transluminal coronary angioplasty (PTCA) within 3 months prior to study
- •Pregnant or lactating or premenopausal with childbearing potential but not taking reliable contraceptive method(s) during the study period Note: Women with childbearing potential should agree to use a highly effective method of birth control, defined as those, alone or in combination, that result in a low failure rate when used consistently and correctly.
- •With the following conditions:
- •ankle brachial index (ABI) < 0.4 OR
- •ABI between 0.4 and 0.6 (inclusive) and not received appropriate treatment for improving venous and arterial insufficiency Note: Subjects with ABI between 0.4 and 0.6 (inclusive) and having received appropriate surgical or endovenous/endovascular therapy for improving venous and arterial insufficiency considered by investigators such as valvuloplasty, angioplasty, or bypass grafting will be eligible to enter the study at investigator's discretion.
- •Enrollment in any investigational drug trial within 4 weeks before entering this study
- •With any condition judged by the investigator that entering the trial may be detrimental to the subject
研究组 & 干预措施
ENERGI-F703
Experimental
ENERGI-F703, topical application, 2 times daily for 12 weeks
干预措施: ENERGI-F703 (Drug)
Placebo
Placebo Comparator
ENERGI-F703 matched vehicle, topical application, 2 times daily for 12 weeks
干预措施: ENERGI-F703 matched vehicle (Drug)
结局指标
主要结局
The ulcer closure rate
时间窗: Week 12
Defined as the proportion of subjects with complete ulcer closure at the end of treatment period
次要结局
- The accumulated confirmed ulcer closure rate at each of the post-treatment visit(Week 1, 2, 4 ,6 ,8, 10, 12)
- The ulcer closure time(Week 1, 2, 4, 6, 8, 10, 12)
- Percentage change in ulcer size for each post-treatment visit(Week 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24)
- Adverse event incidence(Week 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
ENERGI-F701 for Female Hair Loss TreatmentFemale Pattern BaldnessHair LossAlopeciaNCT03351322Energenesis Biomedical Co., Ltd.67
已完成
2 期
EPI-743 in Cobalamin C Defect: Effects on Visual and Neurological ImpairmentMethylmalonic Aciduria and Homocystinuria,Cblc TypeRetinopathyGenetic DiseaseNCT01793090Bambino Gesù Hospital and Research Institute30
已完成
3 期
Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (307)Plaque PsoriasisNCT03731052Therapeutics, Inc.217
已完成
3 期
Study to Evaluate the Efficacy and Safety of P-3073 Nail Solution in the Treatment of Nails Affected by PsoriasisNail PsoriasisNCT02606760Polichem S.A.378
终止
2 期
An Evaluation Of PF-03715455 In Moderate To Severe Chronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic ObstructiveNCT02366637Pfizer13